Buprenorphine Transdermal Matrix Patch — Competitive Intelligence Brief

Buprenorphine Transdermal Matrix Patch (Buprenorphine Transdermal Matrix Patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Partial mu-opioid receptor agonist. Area: Pain Management; Opioid Use Disorder.

phase 3 Partial mu-opioid receptor agonist Mu-opioid receptor (μ-OR) Pain Management; Opioid Use Disorder Small molecule

Target snapshot

Buprenorphine Transdermal Matrix Patch (Buprenorphine Transdermal Matrix Patch) — Washington University School of Medicine. Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Buprenorphine Transdermal Matrix Patch TARGET	Buprenorphine Transdermal Matrix Patch	Washington University School of Medicine	phase 3	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Transmucosal Buprenorphine	Transmucosal Buprenorphine	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
TM buprenorphine	TM buprenorphine	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)
Sublingual Buprenorphine (SLB)	Sublingual Buprenorphine (SLB)	NYU Langone Health	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Subutex (SCH 028444)	Subutex (SCH 028444)	Merck Sharp & Dohme LLC	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)
Buprenorphine (Experimental)	Buprenorphine (Experimental)	University of Alabama at Birmingham	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Use of buprenorphine with FAO > 30 OME	Use of buprenorphine with FAO > 30 OME	Fox Chase Cancer Center	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Partial mu-opioid receptor agonist class)

1. Indivior Inc. · 3 drugs in this class
2. New York State Psychiatric Institute · 3 drugs in this class
3. Orexo AB · 2 drugs in this class
4. BioDelivery Sciences International · 2 drugs in this class
5. King's College London · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. Mundipharma (China) Pharmaceutical Co. Ltd · 1 drug in this class
8. NYU Langone Health · 1 drug in this class
9. National Institute on Drug Abuse (NIDA) · 1 drug in this class
10. Purdue Pharma LP · 1 drug in this class